Shares of bluebird bio Inc (NASDAQ:BLUE) have been given a consensus recommendation of “Hold” by the twenty-five ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $167.00.
A number of equities analysts recently issued reports on BLUE shares. Evercore ISI upgraded shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price objective for the company in a research report on Monday, October 16th. BMO Capital Markets boosted their target price on shares of bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a report on Monday, October 30th. Cantor Fitzgerald reissued a “sell” rating and set a $58.00 target price (up from $39.00) on shares of bluebird bio in a report on Wednesday, November 1st. Leerink Swann reissued an “outperform” rating and set a $162.00 target price (up from $145.00) on shares of bluebird bio in a report on Wednesday, November 1st. Finally, BTIG Research raised shares of bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 target price on the stock in a report on Thursday, November 2nd.
In other news, insider David Davidson sold 4,000 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $202.36, for a total value of $809,440.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Nick Leschly sold 117,500 shares of the company’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $184.08, for a total transaction of $21,629,400.00. Following the completion of the sale, the insider now directly owns 293,232 shares in the company, valued at $53,978,146.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 200,280 shares of company stock worth $37,818,846. Insiders own 3.90% of the company’s stock.
bluebird bio (NASDAQ:BLUE) traded up $1.00 during mid-day trading on Friday, reaching $191.80. 988,183 shares of the company were exchanged, compared to its average volume of 927,083. The firm has a market cap of $8,840.00, a PE ratio of -27.36 and a beta of 2.07. bluebird bio has a twelve month low of $73.50 and a twelve month high of $222.03.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/10/bluebird-bio-inc-blue-given-consensus-rating-of-hold-by-brokerages.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.